Medicines and Healthcare products Regulatory Agency
The UK medicines and devices regulator, which since Brexit runs its own approvals, joins Project Orbis and uses international reliance routes to speed cancer drug access.
Overview
Formed in 2003 by merging the Medicines Control Agency and the Medical Devices Agency, the MHRA became the UK's standalone regulator for new medicines after the UK left the EU in 2021. It participates in the FDA-led Project Orbis and the Access Consortium (with Australia, Canada, Singapore and Switzerland), uses the International Recognition Procedure to rely on approvals by trusted regulators, and runs the Innovative Licensing and Access Pathway with NICE and the Scottish Medicines Consortium to align licensing and reimbursement. The MHRA also regulates clinical trials, devices including AI software, and blood and tissue products, and operates the Yellow Card safety scheme.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Medicines and Healthcare products Regulatory Agency, including child institutions. 12 works · 203 citations · 83% open access · 42% clinical trials · 0% reviews.
- Khadija Rerhou Rantell4 works
- Sandrine Vessillier3 works
- Eddie Han Pin Tan2 works
- Johannes Maria Giesinger2 works
- Anthony Ratcliffe2 works
- Kim Cocks2 works
- Carl G. Simon2 works
- Kathy Rose Oliver2 works
- Linda Peltier2 works
- Jaap C. Reijneveld2 works
- Project Orbis and Access Consortium
- International Recognition Procedure
- Innovative Licensing and Access Pathway (with NICE and SMC)
- Clinical trials and device regulation